TY - JOUR
T1 - Clinical outcomes after hybrid coronary revascularization versus coronary artery bypass surgery
T2 - A meta-analysis of 1,190 patients
AU - Harskamp, Ralf E.
AU - Bagai, Akshay
AU - Halkos, Michael E.
AU - Rao, Sunil V.
AU - Bachinsky, William B.
AU - Patel, Manesh R.
AU - De Winter, Robbert J.
AU - Peterson, Eric D.
AU - Alexander, John H.
AU - Lopes, Renato D.
N1 - Funding Information:
Drs Harskamp, Bagai, Bachinsky, and de Winter do not report any relevant disclosures. Dr Rao receives research grants from Cordis Corportation, Ikaria, and Sanofi-Aventis and received consulting fees for Zoll, the Medicines Company, Terumo Medical, and Daiichi Sankyo Lilly. Dr Patel receives research funding from MAQUET Cardiovascular, Johnson & Johnson, The National Heart, Lung, and Blood Institute, and Agency for Healthcare Research and Quality's and consulting fees from Genzyme corporation. Dr Peterson receives research grants from Abbott Laboratories, Abiomed, Acorn Cardiovascular, and Aastrom Biosciences. Dr Alexander receives support from Bristol Myers Squibb, CLS Behring, the National Institutes of Health, and Regado Biosciences and consulting fees from Moerae Matrix and VA Cooperative Studies program. Dr Lopes receives research funding from Bristol Myers Squibb and Somahlution Inc.
PY - 2014/4
Y1 - 2014/4
N2 - Background Hybrid coronary revascularization (HCR) represents a minimally invasive revascularization strategy in which the durability of the internal mammary artery to left anterior descending artery graft is combined with percutaneous coronary intervention to treat remaining lesions. We performed a systematic review and meta-analysis to compare clinical outcomes after HCR with conventional coronary artery bypass graft (CABG) surgery. Methods A comprehensive EMBASE and PUBMED search was performed for comparative studies evaluating in-hospital and 1-year death, myocardial infarction (MI), stroke, and repeat revascularization. Results Six observational studies (1 case control, 5 propensity adjusted) comprising 1,190 patients were included; 366 (30.8%) patients underwent HCR (185 staged and 181 concurrent), and 824 (69.2%) were treated with CABG (786 off-pump, 38 on-pump). Drug-eluting stents were used in 328 (89.6%) patients undergoing HCR. Hybrid coronary revascularization was associated with lower in-hospital need for blood transfusions, shorter length of stay, and faster return to work. No significant differences were found for the composite of death, MI, stroke, or repeat revascularization during hospitalization (odds ratio 0.63, 95% CI 0.25-1.58, P =.33) and at 1-year follow-up (odds ratio 0.49, 95% CI 0.20-1.24, P =.13). Comparisons of individual components showed no difference in all-cause mortality, MI, or stroke, but higher repeat revascularization among patients treated with HCR. Conclusions Hybrid coronary revascularization is associated with lower morbidity and similar in-hospital and 1-year major adverse cerebrovascular or cardiac events rates, but greater requirement for repeat revascularization compared with CABG. Further exploration of this strategy with adequately powered randomized trials is warranted.
AB - Background Hybrid coronary revascularization (HCR) represents a minimally invasive revascularization strategy in which the durability of the internal mammary artery to left anterior descending artery graft is combined with percutaneous coronary intervention to treat remaining lesions. We performed a systematic review and meta-analysis to compare clinical outcomes after HCR with conventional coronary artery bypass graft (CABG) surgery. Methods A comprehensive EMBASE and PUBMED search was performed for comparative studies evaluating in-hospital and 1-year death, myocardial infarction (MI), stroke, and repeat revascularization. Results Six observational studies (1 case control, 5 propensity adjusted) comprising 1,190 patients were included; 366 (30.8%) patients underwent HCR (185 staged and 181 concurrent), and 824 (69.2%) were treated with CABG (786 off-pump, 38 on-pump). Drug-eluting stents were used in 328 (89.6%) patients undergoing HCR. Hybrid coronary revascularization was associated with lower in-hospital need for blood transfusions, shorter length of stay, and faster return to work. No significant differences were found for the composite of death, MI, stroke, or repeat revascularization during hospitalization (odds ratio 0.63, 95% CI 0.25-1.58, P =.33) and at 1-year follow-up (odds ratio 0.49, 95% CI 0.20-1.24, P =.13). Comparisons of individual components showed no difference in all-cause mortality, MI, or stroke, but higher repeat revascularization among patients treated with HCR. Conclusions Hybrid coronary revascularization is associated with lower morbidity and similar in-hospital and 1-year major adverse cerebrovascular or cardiac events rates, but greater requirement for repeat revascularization compared with CABG. Further exploration of this strategy with adequately powered randomized trials is warranted.
UR - http://www.scopus.com/inward/record.url?scp=84897033979&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84897033979&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2014.01.006
DO - 10.1016/j.ahj.2014.01.006
M3 - Article
C2 - 24655709
AN - SCOPUS:84897033979
SN - 0002-8703
VL - 167
SP - 585
EP - 592
JO - American heart journal
JF - American heart journal
IS - 4
ER -